Vinpotropil, 10 mg+800 mg 30 pcs

Nootropic combined drug, also has vasodilator properties. Improves cerebral blood flow, causes a slight decrease in systemic BP.

Increases resistance of brain cells to hypoxia, facilitates transport of oxygen and energy supply substrates to tissues (due to decreased affinity of red blood cells for oxygen, increased absorption and metabolism of glucose and transition to aerobic processes). It promotes the accumulation of cAMP and ATP in tissues and increases the content of catecholamines in brain tissues. Vasodilator effect is associated with a direct relaxing effect on vascular smooth muscle mainly of the brain.

The drug does not cause the phenomenon of stealing and increases blood supply to the ischemic area of the brain without affecting the blood supply to intact areas. It improves microcirculation in the brain by reducing platelet aggregation, decreasing blood viscosity, increasing red blood cell deformability. It has a positive effect on metabolic processes in brain cells, increases the concentration of ATP in the brain tissue, increases the synthesis of ribonucleic acid and phospholipids, as well as glucose utilization.

It improves integrative activity of the brain, promotes memory consolidation, facilitates learning, changes the speed of excitation in the brain. It increases alpha and beta activity, decreases delta activity on EEG, reduces vestibular nystagmus severity, improves connections between hemispheres and synaptic conduction in neocortical structures, increases mental alertness, increases cerebral blood flow, has no sedative and psychostimulant effect. The action of the drug develops gradually.

Indications

– cerebrovascular insufficiency (recovery period of ischemic and hemorrhagic stroke, encephalopathy of various origins);

Pharmacological effect

A nootropic combination drug that also has vasodilating properties. Improves cerebral circulation and causes a slight decrease in systemic blood pressure.

Increases the resistance of brain cells to hypoxia, facilitates the transport of oxygen and energy supply substrates to tissues (due to a decrease in the affinity of red blood cells for oxygen, increased absorption and metabolism of glucose, and a transition to aerobic processes). Promotes the accumulation of cAMP and ATP in tissues, increasing the content of catecholamines in brain tissues. The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of blood vessels, mainly in the brain.

The drug does not cause the steal phenomenon and increases blood supply to the ischemic area of ​​the brain without affecting the blood supply to intact areas. Improves microcirculation in the brain by reducing platelet aggregation, reducing blood viscosity, and increasing the deformability of red blood cells. It has a positive effect on metabolic processes in brain cells, increases the concentration of ATP in brain tissue, enhances the synthesis of ribonucleic acid and phospholipids, as well as the utilization of glucose.

Improves the integrative activity of the brain, promotes memory consolidation, facilitates the learning process, and changes the speed of spread of excitation in the brain. Enhances alpha and beta activity, reduces delta activity on the EEG, reduces the severity of vestibular nystagmus, improves connections between the hemispheres and synaptic conduction in neocortical structures, increases mental activity, increases cerebral blood flow, and does not have a sedative or psychostimulating effect.
The effect of the drug develops gradually.

Special instructions

Before discontinuing the drug, the dose of Vinpotropil should be reduced gradually.

Active ingredient

Vinpocetine, Piracetam

Composition

Active substances:

Pregnancy

The drug is contraindicated during pregnancy and lactation.

Contraindications

– severe heart rhythm disturbances;

Side Effects

From the side of the central nervous system: mental and motor agitation, irritability, imbalance, decreased ability to concentrate, anxiety, sleep disturbances, dizziness, headache, extrapyramidal disorders.

From the digestive system: gastralgia, nausea, vomiting, constipation, diarrhea, loss of appetite.

From the cardiovascular system: worsening of angina pectoris, tachycardia, extrasystole, slowdown of AV conduction.

Other: increased sexual activity.
The drug is well tolerated. Side effects are observed in rare cases.

Interaction

When used together, Vinpotropil increases the risk of hemorrhagic complications of heparin therapy, enhances the effects of thyroid hormones, antipsychotics (neuroleptics), and indirect anticoagulants.

When used simultaneously, Vinpotropil weakens the effect of anticonvulsants (lowers the seizure threshold).

Overdose

Data on overdose of the drug Vinpotropil are not provided.

Recommendations for use

For adults and adolescents over 14 years of age, the drug is prescribed 1-2 capsules 3 times a day.

Maintenance dose – 1 capsule 3 times/day. The duration of treatment ranges from 2-3 weeks to 2-6 months.

Capsules should be taken without chewing, before meals, with a sufficient amount of water.

Storage conditions

List B. The drug should be stored in a dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C.

Shelf life

2 years

Manufacturer

Kanonpharma production CJSC, Russia